2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
187
Myelodysplastic Syndromes
82
Leukemia
39
Leukemia, Myelomonocytic, Chronic
36
Recurrence
24
Myeloproliferative Disorders
15
Congenital Abnormalities
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma, Large B-Cell, Diffuse
13
Neoplasms
11
Primary Myelofibrosis
9
Melanoma
9
Blast Crisis
9
Thrombocythemia, Essential
7
Polycythemia Vera
7
Leukemia, Myelomonocytic, Acute
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Leukemia, Monocytic, Acute
7
Hodgkin Disease
7
Carcinoma, Non-Small-Cell Lung
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Ovarian Neoplasms
6
Myelodysplastic-Myeloproliferative Diseases
6
Anemia, Refractory, with Excess of Blasts
6
Neoplasm Metastasis
5
Lymphoma
5
Leukemia, Myeloid, Accelerated Phase
5
Leukemia, Biphenotypic, Acute
5
Lymphoma, Non-Hodgkin
4
Lung Neoplasms
4
Interventions
Specimen Handling
1
Imatinib Mesylate
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Decitabine
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled